Dov Goldstein, M.D., M.B.A.
Dr. Goldstein brings to the NeuBase board of directors more than two decades of experience in the biopharmaceutical industry as a venture capital investor, an executive and a member of the boards of directors of a number of successful companies including ADMA Biologics (ADMA), Cempra Pharmaceuticals (CEMP), Durata Therapeutics, and Loxo Oncology (LOXO). The companies where Dr. Goldstein has played a leadership role have resulted in the approval of 2 drugs: Eraxis (anidulafungin) and Dalvance (dalbavancin. Dr. Goldstein was the chief financial officer of Schrödinger, LLC from 2017 to 2018. Dr. Goldstein served as a Managing Partner at Aisling Capital, a healthcare dedicated private investment firm, from 2014 to October 2017, Partner from 2008 to 2014 and a Principal at Aisling Capital from 2006 to 2008. Dr. Goldstein served as the chief financial officer of Loxo Oncology, Inc. between July 2014 and January 2015, and was its acting chief financial officer from January 2015 to May 2015. From 2000 to 2005, Dr. Goldstein served as chief financial officer of Vicuron Pharmaceuticals, Inc., which was acquired by Pfizer, Inc. in September 2005, and helped lead the M&A process. Prior to joining Vicuron, Dr. Goldstein was director of venture analysis at HealthCare Ventures. Dr. Goldstein serves as a director and chairman of the compensation committee of ADMA Biologics, Inc. (Nasdaq: ADMA). He serves as a director and member of the audit committee of Esperion Therapeutics (ESPR).. Dr. Goldstein received a B.S. from Stanford University, an MBA from Columbia Business School and an M.D. from Yale School of Medicine.